>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
16.8 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Dectin-1, also known as CLEC7A and the beta -glucan receptor, is a 33 kDa type II transmembrane C-type lectin that participates in the innate immune response to fungal pathogens. Although Dectin-1 structurally resembles other CLEC molecules, it binds its ligands in a calcium-independent manner (1, 2). Mature human Dectin-1 consists of a short N-terminal ITAM-containing cytoplasmic tail, a transmembrane segment, and a C-terminal stalk with a carbohydrate recognition domain (CRD) in the extracellular domain (3, 4). Alternate splicing generates one major splice form that lacks the stalk region (3 - 5). This isoform is expressed on the surface of monocytes, macrophages, myeloid DC, neutrophils, eosinophils, B cells, and CD4+ T cells (6). The CRD selectively binds beta -glucan polymers, a major component of yeast and mycobacterial cell walls (5 - 7). Yeast beta -glucan is accessible to Dectin-1 only during the process of cell budding. Dectin-1 does not recognize the filamentous form of yeast (8). Dectin-1 mediates the phagocytosis of zymosan particles and intact yeast (8 - 10). In the membrane, Dectin-1 colocalizes with TLR2 in the presence of zymosan, and the two receptors cooperate in ligand recognition and the propagation of proinflammatory signaling (9, 11 - 13). Dectin-1 also interacts with tetraspanin CD37. This increases its stability on the cell membrane and inhibits ligand-induced signaling (14). Dectin-1 knockout mice show increased susceptibility to pathogenic infection (15 - 16). The CRD of human Dectin-1 shares 77%, 60%, and 60% amino acid (aa) sequence identity with that of bovine, mouse and rat Dectin-1, respectively. It shares 29% - 39% aa sequence identity with the CRD of other subgroup members, including CLEC-1, CLEC-2, CLEC9A, CLEC12B, LOX-1, and MICL.
Kanazawa, N. (2007) J. Dermatol. Sci. 45:77.
Brown, G.D. (2006) Nat. Rev. Immunol. 6:33.
Hernanz-Falcon, P. et al. (2001) Immunogenetics 53:288.
Yokota, K. et al. (2001) Gene 272:51.
Willment, J.A. et al. (2001) J. Biol. Chem. 276:43818.
Willment, J.A. et al. (2005) Eur. J. Immunol. 35:1539.
Palma, A.S. et al. (2006) J. Biol. Chem. 281:5771.
Gantner, B.N. et al. (2005) EMBO J. 24:1277.
Gantner, B.N. et al. (2003) J. Exp. Med. 197:1107.
Kennedy, A.D. et al. (2007) Eur. J. Immunol. 37:467.
Brown, G.D. et al. (2003) J. Exp. Med. 197:1119.
Yadav, M. and J.S. Schorey (2006) Blood 108:3168.
Suram, S. et al. (2006) J. Biol. Chem. 281:5506.
Meyer-Wentrup, F. et al. (2007) J. Immunol. 178:154.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Recombinant Human Dectin-1/CLEC7A Protein, CF and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.